Cutaneous T-Cell Lymphoma: FDA Updates

August 8, 2018 – The U.S. Food and Drug Administration (FDA) approved the use of Mogamulizumab-kpkc (Poteligeo) for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. More Information.